Supernus CEO Jack Khattar Receives 29,849-Share Award

What Happened

• Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), acquired 29,849 shares on 2026-07-29 as a grant/award (derivative) reported at a $0.00 purchase price. This was an award/settlement (transaction code A), not an open-market purchase or sale — typically reflecting compensation that vested or was settled.

Key Details

• Transaction date: 2026-07-29; Report filed: 2026-07-31 (filed within the standard reporting window).
• Transaction type/code: Award/Grant (A); price reported: $0.00; nature: derivative acquisition.
• Footnote: The filing notes these relate to Performance Share Units awarded on 2025-02-19; a portion vested upon achievement of individual performance objectives established on 2025-05-03.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Not marked late (filed two days after the transaction date).

Context

• This appears to be the settlement/vesting of previously awarded performance-based units rather than a market trade. Such awards are common executive compensation and do not by themselves signal a buy/sell decision by the insider.